News-Press NOW

Amphastar Announces FDA Approval for Ipratropium Bromide HFA

RANCHO CUCAMONGA, CA / / February 24, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the U.S. Food and ...

Amphastar FDA Wins And Pipeline Expansion Contrast With Weak Earnings And Valuation

Amphastar Pharmaceuticals (NasdaqGS:AMPH) received FDA approvals for iron sucrose and teriparatide injections. The company ...
WebMD

Ipratropium Nasal - Uses, Side Effects, and More

Overview: Nasal ipratropium is used to help reduce symptoms of a runny nose. It works by reducing the amount of liquid and mucus made in your nose. Common side effects can include dryness of the nose, ...
Finanznachrichten

FDA Approves Combivent Respimat (ipratropium bromide and albuterol) Inhalation Spray for the Treatment of Patients with Chronic Obstructive Pulmonary Disease

Ipratropium bromide, a component of COMBIVENT Inhalation Aerosol and COMBIVENT RESPIMAT, is an anticholinergic and may cause urinary retention. Therefore, caution is advised when administering either ...

Amphastar outlines mid- to high-single-digit revenue growth for 2026 while launching new respiratory product

Q4 2025 earnings call recap: ipratropium HFA launch, 2026 revenue guidance, margins, BAQSIMI growth and pipeline updates—read now.
Medindia

Side effect(s) of Ipratropium Bromide

Review the side-effects of Ipratropium Bromide as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In ...